Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells C$73,503.54 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 7,569 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of C$9.71, for a total value of C$73,503.54.

Rostislav Christov Raykov also recently made the following trade(s):

• On Wednesday, February 5th, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$9.66, for a total transaction of C$23,476.17.
• On Monday, January 6th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$8.76, for a total transaction of C$87,552.00.
• On Friday, December 20th, Rostislav Christov Raykov bought 25,000 shares of Fennec Pharmaceuticals stock. The stock was purchased at an average price of C$3.87 per share, with a total value of C$96,840.00.

Fennec Pharmaceuticals Stock Down 10.3 %

TSE FRX traded down C$1.01 during trading hours on Monday, reaching C$8.81. 2,319 shares of the company traded hands, compared to its average volume of 1,583. The stock has a market capitalization of C$169.90 million, a PE ratio of -149.24 and a beta of 0.25. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. Fennec Pharmaceuticals Inc. has a 12 month low of C$5.65 and a 12 month high of C$15.20. The company has a 50 day moving average of C$9.18 and a two-hundred day moving average of C$7.88.

Analysts Set New Price Targets

Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a "strong-buy" rating in a report on Monday, November 18th.

Remove Ads

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.